MedTrace Logo

RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow

NCT05062681 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-09-30

No results posted yet for this study

Summary

This study aims to evaluate the therapeutic activity and side effects of 16 mg/day dexamethasone in comparison to equivalent dose of MP (1mg/kg/day)for the management of COVID-19 infected patients.Moreover, and according to the importance of the IL-6/STAT-3 in triggering the inflammatory cascade and as the miRNAs are considered as prognostic markers, hence, the study aims also to study the impact of the used regimens on these biomarkers

Conditions

  • COVID-19 Pandemic

Interventions

DRUG

Dexamethasone

Patients will receive dexamethasone 8 mg q12hours

DRUG

Methylprednisolone

Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mohamed EL-Ayashy, Ass. Professor · Ass. Professor of Anesthesia and Intensive Care

  • Mohamed Farouk Abdelsalam, Consultant · Consultant of Clinical Pharmacy and Clinical Nutrition Al-Galaa Military Medical Complex (GMMC)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2021-12-15
Completion
2022-03-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05062681 on ClinicalTrials.gov